Stay updated on CPX-351 and Quizartinib in AML Clinical Trial

Sign up to get notified when there's something new on the CPX-351 and Quizartinib in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CPX-351 and Quizartinib in AML Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The website footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-01T14:10:42.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A notice appears about NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and provides a link to updates and FAQs.
    Difference
    0.6%
    Check dated 2026-10-25T13:40:26.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2; the study record content remains unchanged.
    Difference
    0.1%
    Check dated 2026-10-18T14:07:18.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site revision in the footer changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-11T13:36:03.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 has been added to the record history, and the previous v3.6.6 entry has been removed.
    Difference
    0.1%
    Check dated 2026-09-20T15:31:37.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The study record history adds a new revision entry v3.6.6. The v3.6.5 entry has been removed, updating the revision log to reflect the latest version of the record.
    Difference
    0.1%
    Check dated 2026-08-30T00:38:18.000Z thumbnail image

Stay in the know with updates to CPX-351 and Quizartinib in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CPX-351 and Quizartinib in AML Clinical Trial page.